Surveillance of Efficacy and Safety of Drug PRITOR in patieNts With Arterial Hypertension, Who do Not Tolerate ACE inhibitoR Treatment

• Status: Completed
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Surveillance of efficacy and safety of drug PRITOR in patieNts with arterial hypertension, who do not tolerate ACE inhibitoR treatment

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Angiotensin-Converting Enzyme Inhibitors; Telmisartan

Criteria

Inclusion Criteria:

• Patients over 18 years of age

• Arterial hypertension (SBP < 160 mmHg and DBP < 100 mmHg)

• Patients, who do not tolerate ACE inhibitors (must be documented in the official ambulant documentation)

Inclusion criteria for the control arm (treated by ACEi):

• Patients over 18 years of age

• Arterial hypertension (SBP < 160 mmHg and DBP < 100 mmHg)

• Patients, who tolerate ACEi treatment

Exclusion Criteria:

• Cholestasis, severe hepatic insufficiency

• Allergy to telmisartan

• Gravidity or lactation

Exclusion criteria for the arm of patient treated by ACEi:

• Cholestasis, severe hepatic insufficiency

• Allergy to ACEi

• Gravidity or lactation